<DOC>
	<DOCNO>NCT00982644</DOCNO>
	<brief_summary>This trial conduct Europe United States America ( USA ) . The aim trial compare NN1250 ( insulin degludec ( IDeg ) ) insulin glargine ( IGlar ) subject type 2 diabetes never treat insulin follow extension trial investigate long-term safety tolerability term compare NN1250 insulin glargine subject type 2 diabetes . All oral anti-diabetic drug ( OAD ) treatment discontinue trial participant enters main trial ( NN1250-3579 ) exception metformin dipeptidyl peptidase-IV ( DPP-IV ) inhibitor treatment ( country DPP-IV inhibitor treatment approve combination treatment together insulin , otherwise DPP-IV inhibitor treatment also discontinue ) . Subjects consent participate extension trial continue treatment ( NN1250 insulin glargine + oral antidiabetic drug ( OADs ) ) randomly allocate 52 week main trial . The main period register internally Novo Nordisk NN1250-3579 extension period register NN1250-3643 .</brief_summary>
	<brief_title>Comparison NN1250 Versus Insulin Glargine Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 2 diabetes mellitus Treatment oral antidiabetic drug ( OADs ) least three month trial start unchanged dose HbA1c : 7.010.0 % Body Mass Index ( BMI ) high 40.0 kg/m^2 For extension trial : Completion 52 week treatment period trial NN12503579 ( NCT00982644 ) Treatment exenatide liraglutide within last 3 month trial start Cardiovascular disease within last 6 month Uncontrolled treated/untreated severe hypertension Pregnancy , breastfeeding , intention become pregnant use adequate contraceptive measure Cancer medical history cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>